VVUS VIVUS Inc.

4.98
+0.01  (+0%)
Previous Close 4.97
Open 4.98
Price To Book -1.46
Market Cap 52937017
Shares 10,629,923
Volume 55,066
Short Ratio
Av. Daily Volume 199,487

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved July 17, 2012.
Qnexa
Obesity
Approved Apr 27 2012. sNDA label change also approved 17 Sept 2014
Avanafil
Erectile dysfunction
Phase 1 trial completed July 2018.
VI-0106
Pulmonary arterial hypertension (PAH)

Latest News

  1. VIVUS to Host Fourth Quarter and Full Year Business Update and Financial Results Conference Call on Tuesday, February 26, 2019
  2. 3 Biotech Stocks That Pay Solid Dividends
  3. VIVUS Announces Date of 2019 Annual Meeting
  4. Today's Research Reports on Trending Tickers: Array BioPharma and VIVUS
  5. Data Supporting the Cardiovascular Safety of VIVUS’ Qsymia® Published in The Journal of Clinical Endocrinology & Metabolism
  6. VIVUS (VVUS) Banks on New Drug Pancreaze, Qsymia Lacks Luster
  7. VIVUS to Present at Biotech Showcase on January 9, 2019
  8. Do Institutions Own Shares In VIVUS, Inc. (NASDAQ:VVUS)?
  9. 5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride
  10. The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen
  11. Vivus (VVUS) Down 17% Since Last Earnings Report: Can It Rebound?
  12. New Research Coverage Highlights CommVault, Dawson Geophysical, RF Industries, Hennessy Advisors, VIVUS, and Semiconductor Manufacturing International — Consolidated Revenues, Company Growth, and Expectations for 2018
  13. Edited Transcript of VVUS earnings conference call or presentation 1-Nov-18 8:30pm GMT
  14. VIVUS (VVUS) Q3 Loss Narrower Than Expected, Revenues Up Y/Y
  15. Vivus: 3Q Earnings Snapshot
  16. VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Thursday, November 1, 2018

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19595870
  2. 8-K - Current report 19563712
  3. 8-K - Current report 19543699
  4. SC 13G - Statement of acquisition of beneficial ownership by individuals 19533429
  5. 8-K - Current report 19523643
  6. 8-K - Current report 19512174
  7. CT ORDER - Confidential treatment order 181247034
  8. 8-K - Current report 181230992
  9. 8-K - Current report 181202048
  10. 8-K - Current report 181162986